Picking a PI in Multiple Myeloma: Asking & Answering the W5

Release date: December 12, 2019
Expiration date: December 12, 2020
Estimated time to complete activity: 30 minutes

 

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona

PROGRAM OVERVIEW

Once considered an inevitable death sentence within a matter of months, multiple myeloma (MM) can now, in many cases, be transformed into a long-term chronic illness that can often be managed for decades. Recent advances in genomics and gene sequencing have led to a better understanding of the myeloma microenvironment in the pathophysiology of MM, which has in turn yielded new therapies that target the diseases through immunomodulatory, cellular, and genetic pathways. Proteasome inhibitors (PIs), specifically, are used across the continuum of care, and have become the backbone of treatment combinations in the relapsed/refractory MM (RRMM) setting, particularly in high-risk disease. However, there is no one standard of care for this disease, due to its complex and nuanced nature. This activity is designed to highlight optimal treatment combinations for standardized case study patients based on a wide variety of patient variabilities, including cytogenetic abnormalities, stage and age at diagnosis, whether and when autologous stem cell transplant (ASCT) might be performed, and multiple other prognostic factors.

TARGET AUDIENCE

This educational activity is intended for specialists in hematology (hematologists/oncologists), oncology (medical and radiation oncologists), and physician assistants and nurse practitioners who manage patients with MM.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Differentiate between the PIs, outlining the efficacy and safety profiles, advantages and disadvantages, and quality of life impact of each
  • Select tailored treatment combinations for a cytogenetically high-risk MM patient at first and second relapse
  • Expound the rationale for PI-based treatment combinations for patients with RRMM
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of December 12, 2019 through December 12, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Joseph Mikhael, MD, Med, FRCPC, FACP
Consulting Fees: Amgen; Celgene; Karyopharm; Janssen; Sanofi; Takeda

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Takeda Oncology.

Continue to Pretest